Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.

In this meta-analysis, researchers evaluated the use and/or prolongation of ADT in men with non-metastatic prostate cancer undergoing definitive radiotherapy. For men with prostate cancer treated with ...

Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of ...

Moderately hypofractionated radiotherapy, both isodose and dose-escalated, led to progression-free survival outcomes similar to that achieved with conventionally fractionated radiotherapy in patients ...

Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of ...

Prostate cancer is the second most common cancer for American men, yet receiving a diagnosis can feel unexpected. [1] While some people experience symptoms like increased frequency of difficulty ...

Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as ...

Hypofractionation of radiation therapy in men with high-risk prostate cancer is not associated with worse overall survival or prostate cancer mortality. Survival outcomes are comparable after ...

Treatments for prostate cancers localised to the prostate have long been aimed at treating the whole prostate either by ...

Mack Roach, III, MD, FASTRO, has been chosen by the American Society for Radiation Oncology (ASTRO) to receive its 2024 Gold Medal Award. Roach is being recognized with ASTRO’s highest honor for his ...

So far, “the only established risk factors for prostate cancer are advancing age, African ancestry, and a family history of ...